Company intelligence / Profile preview
Cirius Therapeutics
San Diego, California, USAciriustx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Cirius Therapeutics’ lead candidate, azemiglitazone potassium (MSDC‑0602K), has completed a Phase IIb trial in patients with MASH and type 2 diabetes. Data presented in June 2024 showed that azemiglitazone may preserve lean muscle mass when combined with GLP‑1 receptor agonists and improve metabolic parameters. The company’s approach targets the mitochondrial pyruvate carrier to reduce insulin resistance and address multiple metabolic diseases including T2D, obesity, and MASH.
- Therapeutic areas
- EndocrinologyCardiovascularMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major disclosed pharma partnerships as of May 2025; academic collaboration with Dr. Kyle McCommis lab at St. Louis University for preclinical research
Beyond the preview
Go deeper on Cirius Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cirius Therapeutics.